IntraLuminal Therapeutics Inc.

  
Generate a summary of this article
Listen to this article
Beta

IntraLuminal Therapeutics is developing a new guidance system designed to help interventional cardiologists safely cross total occlusions.

For all of the recent advances that have taken place in interventional cardiology, one of the most vexing remaining problems is the difficulty presented by chronic total occlusions (CTOs), which are arterial vessel blockages that preclude blood flow distal of the blockage. A recently completed international multi-center five-year study reported one or more CTOs in 31% of all angiographic procedures studied. This translates to one million coronary procedures and 900,000 peripheral vascular procedures performed worldwide in 1999 in which a patient will be found to have at least one chronic total occlusion.

The problem CTOs pose for interventional cardiologists lies in safely crossing and carving out a channel, or recanalizing, through the...

Medtech Insight Podcast

Keep up with the top medtech business and regulatory news.

Medtech Insight brings you interviews and analysis, on the go.

SpotifyApple PodcastsWebsite

More from Archive

  • Iran Deal In Place, But API Prices Stay Elevated And Pharma Supply Chains Face A Slow Recovery

    A framework to end the Iran war is in place but fractured supply chains can’t recover overnight. Data from India suggests solvent prices have generally cooled from April peaks, but API costs stay elevated or even climbed in June for some products.

  • Cardiac catheter reuse targeted by FDA; lab testing of used catheters planned.

    REUSE OF DISPOSABLE CARDIAC CATHETERS TARGETED BY FDA in an effort to address safety concerns about reuse of single-use products. The cardiac catheter product area "seems to jump up as one that is an area for us to focus on," Larry Spears, director of the Office of Compliance's Division of Enforcement III in FDA's Center for Devices and Radiological Health, said June 24 at a Food Drug and Law Institute conference held in Washington, D.C.

  • Heart valve sewing cuffs to be developed:

    St Jude Medical and Spire are to develop anti-bacterial heart valve sewing cuffs using Spire's Spi-Argent silver coating process. The agreement covers a variety of valve designs as well as ancillary components. The treatment is aimed at reducing the incidence of endocarditis, a rare but dangerous complication of valve transplant which has a mortality rate as high as 60%.

  • Nissho sales flat at only 1% in 1997:

    Nissho saw sales rise only 1% to ¥17 billion ($930 million) in the year to March 1997. The Japanese company's net income was Yen3 billion, compared with Yen1.7 billion for the previous year, reports Reuters. Nissho produces disposable medical equipment.

More from Medtech Insight